Loading
A phase 1/2 trial of Ipilimumab, Nivolumab, Gemcitabine in mesothelioma and non-small-cell lung cancer, run by Orion Corporation, Orion Pharma, now recruiting.
A 2-part Phase 1/2 Open-label Trial on ODM-212 is a phase 1/2 interventional study registered as NCT07563738 by Orion Corporation, Orion Pharma, with 229 participants planned, started 2026-03-27 and due to reach its primary completion in 2029-09. Interventions recorded: ODM-212, Ipilimumab and nivolumab, Gemcitabine and nab-paclitaxel, sotorasib. Conditions listed: Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ipilimumab, Paclitaxel / nab-paclitaxel, Nivolumab, Non-small-cell lung cancer.
Shares Mesothelioma, Ipilimumab, Nivolumab.
Shares Mesothelioma, Ipilimumab, Nivolumab, Non-small-cell lung cancer.
Shares Mesothelioma, Ipilimumab, Nivolumab.
Shares Ipilimumab, Nivolumab, Non-small-cell lung cancer.
Shares Ipilimumab, Nivolumab, Non-small-cell lung cancer.
Shares Mesothelioma, Ipilimumab, Nivolumab.
Shares Ipilimumab, Gemcitabine, Nivolumab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/